comparemela.com

Latest Breaking News On - Bryan baldasare - Page 3 : comparemela.com

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

/PRNewswire/ Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced.

Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021

/PRNewswire/ Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report.

Meridian Bioscience to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on November 12, 2021

/PRNewswire/ Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report.

Meridian Bioscience Inc (VIVO) Q2 2021 Earnings Call Transcript

Operator Good afternoon and thank you for standing by. Welcome to the Meridian Bioscience Fiscal Second Quarter 2021 Earnings Conference Call. [Operator Instructions] Now, I would like to hand the call over to Vice President of Investor Relations, Charlie Wood. Please go ahead. Charles Wood Vice President, Corporate Strategy, Business Development & Investor Relations Thank you, Holly. Good morning and welcome to Meridian s fiscal 2021 second quarter earnings call. With me are Jack Kenny, Chief Executive Officer and Bryan Baldasare, Chief Financial Officer. Please note that our SEC filings, earnings release and slides to accompany this call are available on our website at investor.meridianbioscience.com. We will post a copy of these prepared remarks after the call.

Meridian Bioscience Reports Strong Growth in Net Revenues and EPS in Second Quarter Fiscal 2021

Message : Required fields CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 million, up 49% year-over-year Life Science segment delivered net revenues of $53.3 million, up 139% year-over-year Diagnostics segment net revenues decreased 9% year-over-year to $31.9 million, up 5% from the first quarter of fiscal 2021 Signed agreement for 2nd grant from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx SM) initiative - $5.5 million for ramping manufacturing of Revogene ® SARS-CoV-2 Assay ® Campy assay Launched first Air-Dryable sample specific Master Mix for Blood

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.